Biomax Announces Early Adopter Program for NeuroXM
Biomax Informatics AG announces an early adopter program for its new product, the NeuroXM™ Brain Science Suite. The NeuroXM suite is a novel technology that standardizes and homogenizes multimodal neuroimaging data sets and increases interoperability of complex brain data in clinics, academic institutions and industry for human brain mapping and patient stratification.
In the early adopter program, potential customers can discuss relevant applications in their field with Biomax Brain Science specialists. By sharing their input, users can influence the final configuration of the first release of NeuroXM suite, which will be launched at the end of the third quarter of 2018.
Interested users and journalists can meet Biomax at the European Neurology congress EAN2018 in Lisbon, Portugal 16–19 June 2018 to learn more about the NeuroXM suite. Biomax neuroscientists will be also available at a Satellite Event of the 11th FENS Forum of Neuroscience of the Federation of European Neuroscience Societies on 6 July 2018 in Berlin, Germany, organized by Biomax and the University of Newcastle. Spaces are limited; to register visit the Biomax website: https://www.biomax.com/symposiums/from-scanner-to-bedside/ .
About the NeuroXM™ Brain Science Suite
The NeuroXM suite has a broad range of applications from basic neuroscience research and neuropharmacology to neurology and psychiatry. Users can customize processing pipelines for their data, use interfaces to the Allen Human Brain Atlas and the Human Connectome Project, etc., and integrate all results into a unified feature space. A built-in query language enables implicit knowledge from multimodal high-dimensional brain data sets to be revealed. New biomarkers, brain connections and molecular targets can be made accessible for further application.
Find out more about NeuroXM Brain Science Suite at www.biomax.com/neuroxm.
Biomax Informatics AG provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources. Biomax’s worldwide customer community includes companies, clinics and research organizations that are successful in healthcare, drug discovery, diagnostics, fine chemicals, food and plant production, and synthetic biology. For more information, visit www.biomax.com.
Biomax, BioXM and NeuroXM are registered trademarks of Biomax Informatics AG in Germany and other countries. Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.
Biomax Informatics AG
Dr. Markus Butz-Ostendorf
Tel. +49 (0)89 895574-0
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
GHX Exhibiting at MEDICA 2018 – World Forum for Healthcare15.10.2018 08:00 | Pressemelding
Global Healthcare Exchange (GHX), a leader in cloud-based healthcare supply chain management solutions, will be exhibiting at the leading international trade fair for the medical sector, MEDICA 2018, in Düsseldorf, Germany between the 12th and 15th November, 2018. GHX provides a full range of intelligent eCommerce and supply chain solutions specifically designed for the complex world of healthcare. The organisation’s technology connects thousands of healthcare suppliers, manufacturers and distributors with hospitals and GPOs – as well as to Governments for reporting processes. GHX technology enables the right devices, equipment, services and medicines to flow efficiently through the European healthcare supply chain. MEDICA attendees are invited to visit GHX in Hall 16, Stand F20-2, to discover how the organisation’s deep commitment to the healthcare industry, unrivalled understanding of the sector and proactive approach to collaboration to develop best practice, ensures its technology
Intertops Poker satellite sending another winner to the Malta Poker Festival where €500K is guaranteed!15.10.2018 07:06 | Pressemelding
Intertops Poker is sending another online satellite tournament winner to play in the €500,000 guaranteed Malta Poker Festival Main Event that runs from November 1st – 6th at the Portamaso Casino. The $2,500 prize package covers the winner’s buy-in to the Malta Poker Festival Main Event, Day 1C. $500 toward travel expenses is included. The online champion will stay at the posh Hilton Hotel November 2 – 7th. The Intertops team will take them to an exclusive MPF VIP party. The Poker Manager at Intertops Poker, said: “The Malta Poker Festival is a brand new event but I am sure it will be a hit, and there is still chance for players to earn their seat at the tables for the main event. “The festival has it all; it is set in a stunning location, it is playing in a prestigious casino and it has a life-changing prize pot. So if you think you have what it takes to lift the trophy, sign-up for the satellite now. Satellites: To register, open the Intertops Poker lobby, click ‘Poker’ > ‘Tournaments
Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress15.10.2018 07:00 | Pressemelding
Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 October 2018. These primary analyses will contribute to the scientific community’s understanding of both disease states and the clinical profile of dabigatran etexilate (Pradaxa®). The results from RE-SPECT ESUS, the first randomised trial comparing dabigatran etexilate with acetylsalicylic acid (ASA) in any indication, will add further insight into the prevention of secondary stroke in patients with an embolic stroke of undetermined source (ESUS).1 As the first comparison to ASA, this trial will also offer further important insights into the clinical profile of dabigatran etexilate. RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It is the first exploratory, prospective, randomised controlled study of any non-vitamin K anta
IFC and Alipay Announce 10x1000 Tech for Inclusion Programme to Inspire Technology Leaders in Emerging Markets15.10.2018 04:15 | Pressemelding
International Financial Corporation (“IFC”), a member of the World Bank Group, and Ant Financial Services Group (“Ant Financial”), the world’s leading tech company and the operator of Alipay, jointly announced the 10x1000 Tech for Inclusion programme at the 2018 Annual Meetings of the International Monetary Fund and the World Bank Group. The initiative will include a comprehensive programme that embraces interactivity and the exchange of ideas to provide training to 10,000 tech experts in emerging markets from both public and private sectors over the next 10 years. Alibaba Group founder and Executive Chairman Jack Ma said that the programme aims to build an interactive and open platform to increase support for tech leaders and skilled individuals who are working to alleviate poverty and make basic financial services more broadly accessible in Indonesia, which will be the first stop of the programme within emerging markets. “I believe that investing in people is investing for the future
Chugai Presents Results from Phase III Study of Satralizumab in NMOSD at ECTRIMS 201815.10.2018 03:00 | Pressemelding
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that results from the phase III study of satralizumab (development code: SA237), SAkuraSky Study (NCT02028884), were presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2018 held in Berlin, Germany from October 10 to 12. Satralizumab is a humanized investigational recycling anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments. “These positive pivotal results for satralizumab, showing a significant reduction in relapses in patients, are a significant positive step in the potential treatment of NMOSD,” said Dr. Takashi Yamamura, Director, Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo. “Many people with NMOSD are suffering from frequent relapses and often persistent motor dysfunction and loss of sensation, and end up r
Guidewire InsuranceSuite Positioned as a Leader in Gartner's Magic Quadrant for P&C Core Platforms, North America, for Second Consecutive Year14.10.2018 17:10 | Pressemelding
GUIDEWIRE CONNECTIONS 2018–- Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced that Guidewire InsuranceSuite™ has been recognized as a Leader in Gartner, Inc.'s “Magic Quadrant for P&C Core Platforms, North America 1 .” InsuranceSuite comprises essential core systems based on a common technology platform covering the P&C insurance lifecycle including underwriting, policy, billing, and claims management. It was positioned highest on the ability to execute axis and furthest on the completeness of vision axis in the report. The report can be viewed here. “While many vendors are playing to specific strengths, market leaders are expanding the scope of their capabilities with a growing emphasis on broader ecosystems with partners accessible through prebuilt integration in an app-store-like venue. As the number of ecosystem partners grows, this promises customers quicker access to a range of new capabilitie